United Therapeutics Corporation (UTHR) Insider Trading
- $999,400.80
- $1,132,063,419.18
- April 24, 2026
- Martine A Rothblatt
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| April 24, 2026 | Director | 2,910 | $569.00 | Sell | $1,655,790.00 | |
| April 23, 2026 | CFO | 9,636 | $572.21 | Sell | $5,513,815.56 | |
| April 22, 2026 | CEO | 9,500 | $576.56 | Sell | $5,477,320.00 | |
| April 22, 2026 | CFO | 364 | $575.85 | Sell | $209,609.40 | |
| April 20, 2026 | CEO | 9,500 | $577.83 | Sell | $5,489,385.00 | |
| April 20, 2026 | CFO | 10,000 | $577.86 | Sell | $5,778,600.00 | |
| April 17, 2026 | Director | 1,000 | $578.88 | Sell | $578,880.00 | |
| April 17, 2026 | CEO | 9,500 | $586.66 | Sell | $5,573,270.00 | |
| April 16, 2026 | CFO | 10,000 | $577.18 | Sell | $5,771,800.00 | |
| April 16, 2026 | EVP | 8,300 | $576.82 | Sell | $4,787,606.00 | |
| April 15, 2026 | CEO | 9,500 | $580.36 | Sell | $5,513,420.00 | |
| April 13, 2026 | CFO | 10,000 | $574.88 | Sell | $5,748,800.00 | |
| April 13, 2026 | CEO | 9,500 | $574.86 | Sell | $5,461,170.00 | |
| April 10, 2026 | CEO | 9,500 | $569.28 | Sell | $5,408,160.00 | |
| April 9, 2026 | CFO | 10,000 | $577.89 | Sell | $5,778,900.00 | |
| April 8, 2026 | CEO | 9,500 | $580.45 | Sell | $5,514,275.00 | |
| April 6, 2026 | CEO | 9,500 | $558.41 | Sell | $5,304,895.00 | |
| April 6, 2026 | CFO | 10,000 | $558.40 | Sell | $5,584,000.00 | |
| April 2, 2026 | EVP | 8,300 | $565.87 | Sell | $4,696,721.00 | |
| April 2, 2026 | CFO | 10,000 | $561.50 | Sell | $5,615,000.00 | |
| April 1, 2026 | CEO | 9,500 | $581.63 | Sell | $5,525,485.00 | |
| March 26, 2026 | CFO | 10,000 | $535.90 | Sell | $5,359,000.00 | |
| March 26, 2026 | CEO | 9,500 | $535.81 | Sell | $5,090,195.00 | |
| March 23, 2026 | CEO | 9,500 | $527.01 | Sell | $5,006,595.00 | |
| March 23, 2026 | CFO | 10,000 | $527.48 | Sell | $5,274,800.00 | |
| March 20, 2026 | CEO | 9,500 | $524.99 | Sell | $4,987,405.00 | |
| March 19, 2026 | EVP | 8,300 | $529.95 | Sell | $4,398,585.00 | |
| March 18, 2026 | CEO | 9,500 | $529.59 | Sell | $5,031,105.00 | |
| March 16, 2026 | CEO | 516 | $534.99 | Sell | $276,054.84 | |
| March 12, 2026 | CEO | 8,984 | $537.97 | Sell | $4,833,122.48 | |
| March 11, 2026 | CEO | 9,500 | $539.54 | Sell | $5,125,630.00 | |
| March 9, 2026 | CEO | 9,500 | $518.03 | Sell | $4,921,285.00 | |
| March 6, 2026 | CEO | 9,500 | $477.67 | Sell | $4,537,865.00 | |
| March 5, 2026 | EVP | 8,300 | $483.16 | Sell | $4,010,228.00 | |
| March 4, 2026 | CEO | 9,500 | $489.91 | Sell | $4,654,145.00 | |
| March 4, 2026 | Director | 2,000 | $489.42 | Sell | $978,840.00 | |
| March 4, 2026 | Director | 20 | $490.17 | Sell | $9,803.40 | |
| March 4, 2026 | Director | 4,910 | $489.02 | Sell | $2,401,088.20 | |
| Feb. 25, 2026 | Director | 1,000 | $520.00 | Sell | $520,000.00 | |
| Feb. 23, 2026 | COO | 14,440 | $472.13 | Sell | $6,817,557.20 | |
| Feb. 19, 2026 | EVP | 8,300 | $476.34 | Sell | $3,953,622.00 | |
| Feb. 9, 2026 | COO | 22,500 | $474.65 | Sell | $10,679,625.00 | |
| Feb. 5, 2026 | EVP | 8,300 | $483.25 | Sell | $4,010,975.00 | |
| Feb. 3, 2026 | Director | 50 | $474.23 | Sell | $23,711.50 | |
| Feb. 2, 2026 | COO | 22,500 | $470.95 | Sell | $10,596,375.00 | |
| Sept. 24, 2025 | Director | 1,000 | $440.00 | Sell | $440,000.00 | |
| Sept. 24, 2025 | CEO | 4,000 | $434.12 | Sell | $1,736,480.00 | |
| Sept. 22, 2025 | COO | 22,500 | $416.35 | Sell | $9,367,875.00 | |
| Sept. 22, 2025 | CEO | 4,000 | $417.30 | Sell | $1,669,200.00 | |
| Sept. 19, 2025 | Director | 1,800 | $415.43 | Sell | $747,774.00 |
Insiders are both buying and selling United Therapeutics Corporation stock.
The insider traders at United Therapeutics Corporation are: Martine A Rothblatt, Paul A Mahon, Roger Jeffs, Martine A. Rothblatt, Martine Rothblatt, Christopher Causey, Raymond Dwek, John Maxim Ferrari, Michael Benkowitz, James Edgemond, Christopher Patusky, Paul Mahon, David Zaccardelli, Richard Giltner, Nilda Mesa, Tommy G Thompson, Louis W Sullivan, Judy D Olian, Ray Kurzweil, Jan Malcolm, Paul A. Mahon, Tommy G. Thompson, MAHON PAUL A, Louis Sullivan, Judy D. Olian, R Paul Gray, and DWEK RAYMOND
The most active insider trader at United Therapeutics Corporation is Martine A Rothblatt with 412 trades.
Martine A Rothblatt has sold the most United Therapeutics Corporation stock with a total value of $484,452,823.23.
Martine A Rothblatt has bought the most United Therapeutics Corporation stock with a total value of $1,217,751.60.
The most recent insider trade for United Therapeutics Corporation was on April 24, 2026.
The single biggest insider buy for United Therapeutics Corporation was from Martine A Rothblatt with a total value of $466,650.00 on Dec. 21, 2012.
The single biggest insider sell for United Therapeutics Corporation was from Michael Benkowitz with a total value of $10,679,625.00 on Feb. 9, 2026.